Logo
x

Search

Subscribe Now

P-I study

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in Non-Hodgkin's Lymphoma

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in...

  • October 15, 2021
BioFactura Initiates P-I Study of BFI-751 (biosimilar- ustekinumab)

BioFactura Initiates P-I Study of BFI-751 (biosimilar- ustekinumab)

  • May 25, 2021
Meiji Reports Results of P-I Study of DMB-3115 (proposed ustekinumab biosimilar) and Initiate P-III Study for Plaque Psoriasis

Meiji Reports Results of P-I Study of DMB-3115 (proposed ustekinumab biosimilar) and Initiate P-III Study for Plaque Psoriasis

  • May 21, 2021
MatriSys Report Results of MSB-0221 in P-I study for the Topical Treatment of Atopic Dermatitis

MatriSys Report Results of MSB-0221 in P-I study for the Topical Treatment of Atopic Dermatitis

  • February 23, 2021
Samsung Bioepis Initiates P-I Study of SB16 Proposed Biosimilar to Prolia (denosumab)

Samsung Bioepis Initiates P-I Study of SB16 Proposed Biosimilar to Prolia (denosumab)

  • November 11, 2020
JHL Biotech Reports Dosing of its First Patient with JHL1266 (biosimilar- denosumab) in P-I Study in Australia

JHL Biotech Reports Dosing of its First Patient with JHL1266 (biosimilar- denosumab) in P-I Study in Australia

  • May 18, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.